Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines emerging and past therapies for recurrent implantation failure, focusing on three innovative strategies: PBMC, G-CSF, and PRP, but reports no new clinical results.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This study found that mRNA booster vaccinations for SARS-CoV-2 increased protective antibodies without worsening autoimmune disease activity in patients with pemphigus and bullous pemphigoid.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

In this review, the authors discuss the potential for cell therapy, such as hematopoietic stem cell transplantation and mesenchymal stromal cells, to treat severe psoriasis unresponsive to biological therapies, while highlighting the associated risks, costs, and regulatory challenges.

This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.

This study observes that TYK2 inhibition with BMS-986202 may extend hair follicle growth phases and decrease inflammatory cell markers in alopecia areata, suggesting potential for clinical application.

This study tested a hydrogel microneedle patch delivering T reg attractants in mice with alopecia, finding it boosted regulatory T cell numbers at the site, leading to hair regrowth without causing peripheral immunosuppression, suggesting a potential new approach for autoimmune skin disease treatment.

Upadacitinib effectively treats pyoderma gangrenosum.

This case report suggests that topical imiquimod cream may be an effective alternative treatment for generalized discoid lupus erythematosus without systemic involvement.

This study found that phenyl-imidazole sulfonamide derivatives, particularly ISCK03, inhibited c-kit signaling and promoted depigmentation in various experimental settings, suggesting potential use as skin-whitening agents.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This study reported that dupilumab led to significant reduction in skin rash severity and complete hair regrowth in an 11-year-old boy with severe alopecia areata and atopic dermatitis.

This study found that oral biotin supplementation improved outcomes in a mouse model of inflammatory bowel disease by reducing inflammatory cytokine production and enhancing intestinal barrier integrity, suggesting potential therapeutic benefits for IBD patients.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

This study found that imiquimod combined with fish oil in a bigel formulation enhanced antitumor effects and reduced inflammatory side effects in a skin cancer model.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

In this case report, significant hair regrowth was achieved in a young Filipino woman with severe diffuse alopecia areata using a combination of corticosteroids and methotrexate, highlighting the value of traditional therapies in regions with limited access to newer treatments.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

In this study, researchers developed a biocompatible, ROS-responsive hydrogel to deliver miR-665 locally, effectively reducing inflammatory signaling and promoting hair follicle regeneration in an alopecia areata mouse model, offering a promising approach for targeted treatment.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This case report describes an 8-year-old girl with Mixed Connective Tissue Disease who experienced remission after treatment with immunomodulator drugs, highlighting the diagnostic value of anti-U1 RNP antibody testing in children.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.